BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

Black Diamond Therapeutics shares fell after phase II silevertinib data showed NSCLC efficacy and CNS activity, but investors focused on the early nature of the dataset. The results are directionally positive for the drug, yet still too preliminary to fully de-risk the program. The market reaction suggests concern that the current evidence base may not support a stronger valuation re-rating.

Analysis

Black Diamond Therapeutics shares fell after phase II silevertinib data showed NSCLC efficacy and CNS activity, but investors focused on the early nature of the dataset. The results are directionally positive for the drug, yet still too preliminary to fully de-risk the program. The market reaction suggests concern that the current evidence base may not support a stronger valuation re-rating.